## Rishi Puri

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10459602/publications.pdf

Version: 2024-02-01

192	10,596	55 h-index	96
papers	citations		g-index
195	195	195	10062
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients. JAMA - Journal of the American Medical Association, 2016, 316, 2373.	3.8	813
2	Impact of Statins on Serial Coronary Calcification During Atheroma ProgressionÂand Regression. Journal of the American College of Cardiology, 2015, 65, 1273-1282.	1.2	467
3	Conduction Disturbances After Transcatheter Aortic Valve Replacement. Circulation, 2017, 136, 1049-1069.	1.6	386
4	Transcatheter Versus Medical Treatment of Patients With Symptomatic SevereÂTricuspid Regurgitation. Journal of the American College of Cardiology, 2019, 74, 2998-3008.	1.2	302
5	Aortic Bioprosthetic Valve Durability. Journal of the American College of Cardiology, 2017, 70, 1013-1028.	1.2	248
6	Outcomes After Current Transcatheter Tricuspid Valve Intervention. JACC: Cardiovascular Interventions, 2019, 12, 155-165.	1.1	246
7	Association Between Transcatheter Aortic Valve Replacement and Subsequent Infective Endocarditis and In-Hospital Death. JAMA - Journal of the American Medical Association, 2016, 316, 1083.	3.8	241
8	Impact of New-Onset Left Bundle Branch Block and Periprocedural Permanent Pacemaker Implantation on Clinical Outcomes in Patients Undergoing Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2016, 9, e003635.	1.4	234
9	Transcatheter Tricuspid ValveÂlnterventions. Journal of the American College of Cardiology, 2018, 71, 2935-2956.	1.2	214
10	Incidence, Timing, and Predictors of ValveÂHemodynamic Deterioration After Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2016, 67, 644-655.	1.2	205
11	Transcatheter Therapies for Treating Tricuspid Regurgitation. Journal of the American College of Cardiology, 2016, 67, 1829-1845.	1.2	189
12	TAVI or No TAVI: identifying patients unlikely to benefit from transcatheter aortic valve implantation. European Heart Journal, 2016, 37, 2217-2225.	1.0	171
13	Detection by Near-Infrared Spectroscopy of Large Lipid Core Plaques at Culprit Sites in Patients With Acute ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Interventions, 2013, 6, 838-846.	1.1	169
14	Spotty Calcification as a Marker of Accelerated Progression of Coronary Atherosclerosis. Journal of the American College of Cardiology, 2012, 59, 1592-1597.	1.2	164
15	Predictors of Early Cerebrovascular Events in Patients With Aortic Stenosis Undergoing Transcatheter Aortic ValveÂReplacement. Journal of the American College of Cardiology, 2016, 68, 673-684.	1.2	159
16	Transcatheter Aortic Valve Replacement in Patients With Low-Flow, Low-Gradient AorticÂStenosis. Journal of the American College of Cardiology, 2018, 71, 1297-1308.	1.2	152
17	Transcatheter Valve-in-Valve and Valve-in-Ring for Treating Aortic and MitralÂSurgical Prosthetic Dysfunction. Journal of the American College of Cardiology, 2015, 66, 2019-2037.	1.2	143
18	Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURN. European Heart Journal Cardiovascular Imaging, 2014, 15, 380-388.	0.5	139

#	Article	IF	CITATIONS
19	Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction. JACC: Cardiovascular Imaging, 2022, 15, 1308-1321.	2.3	137
20	Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study. European Heart Journal, 2021, 42, 4324-4332.	1.0	135
21	Bioprosthetic Valve Thrombosis. Journal of the American College of Cardiology, 2017, 69, 2193-2211.	1.2	134
22	First-in-Man Experience of a Novel Transcatheter Repair System for Treating Severe Tricuspid Regurgitation. Journal of the American College of Cardiology, 2015, 66, 2475-2483.	1,2	129
23	Effect of Infusion of High-Density Lipoprotein Mimetic Containing Recombinant Apolipoprotein A-I Milano on Coronary Disease in Patients With an Acute Coronary Syndrome in the MILANO-PILOT Trial. JAMA Cardiology, 2018, 3, 806.	3.0	129
24	Incidence, Predictors, and Implications of Permanent Pacemaker Requirement After Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2021, 14, 115-134.	1.1	121
25	Non-HDL Cholesterol and Triglycerides. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 2220-2228.	1.1	119
26	Warfarin and Antiplatelet Therapy VersusÂWarfarin Alone for Treating PatientsÂWithÂAtrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2016, 9, 1706-1717.	1.1	115
27	Incidence, Causes, and Predictors of EarlyÂ(â‰80 Days) and Late Unplanned Hospital Readmissions After TranscatheterÂAortic Valve Replacement. JACC: Cardiovascular Interventions, 2015, 8, 1748-1757.	1.1	110
28	C-Reactive Protein, but not Low-Density Lipoprotein Cholesterol Levels, Associate With Coronary Atheroma Regression and Cardiovascular Events After Maximally Intensive Statin Therapy. Circulation, 2013, 128, 2395-2403.	1.6	109
29	Mitral Regurgitation After TranscatheterÂAorticÂValve Replacement. JACC: Cardiovascular Interventions, 2016, 9, 1603-1614.	1.1	101
30	Transcatheter Tricuspid Valve Repair WithÂa New Transcatheter Coaptation System for the Treatment of Severe Tricuspid Regurgitation. JACC: Cardiovascular Interventions, 2017, 10, 1994-2003.	1.1	96
31	Right Ventricular-Pulmonary Arterial Coupling and Afterload Reserve in Patients Undergoing Transcatheter Tricuspid Valve Repair. Journal of the American College of Cardiology, 2022, 79, 448-461.	1,2	96
32	Effect of Evolocumab on CoronaryÂPlaque Composition. Journal of the American College of Cardiology, 2018, 72, 2012-2021.	1.2	95
33	Clinical Impact of Baseline Right Bundle Branch Block in Patients Undergoing Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2017, 10, 1564-1574.	1.1	87
34	Coronary atheroma volume and cardiovascular events during maximally intensive statin therapy. European Heart Journal, 2013, 34, 3182-3190.	1.0	86
35	Intravascular imaging of vulnerable coronary plaque: current and future concepts. Nature Reviews Cardiology, 2011, 8, 131-139.	6.1	84
36	Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary Atherosclerosis: Results of the Phase 2b, Randomized, Double-Blind, Multicenter, ASSURE Trial. American Journal of Cardiovascular Drugs, 2016, 16, 55-65.	1.0	82

#	Article	lF	CITATIONS
37	Transcarotid Compared With Other Alternative Access Routes for Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2018, 11, e006388.	1.4	80
38	Rate, Timing, Correlates, and Outcomes of Hemodynamic Valve Deterioration After Bioprosthetic Surgical Aortic Valve Replacement. Circulation, 2018, 138, 971-985.	1.6	77
39	Systematic Approach to High Implantation of SAPIEN-3 Valve Achieves a Lower Rate of Conduction Abnormalities Including Pacemaker Implantation. Circulation: Cardiovascular Interventions, 2021, 14, e009407.	1.4	77
40	Cardiovascular Magnetic Resonance to Evaluate Aortic Regurgitation After Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2016, 68, 577-585.	1.2	74
41	Optimizing Outcomes During Left Main Percutaneous Coronary Intervention With Intravascular Ultrasound and Fractional Flow Reserve. JACC: Cardiovascular Interventions, 2012, 5, 697-707.	1.1	72
42	Coronary arterial calcification: A review of mechanisms, promoters and imaging. Trends in Cardiovascular Medicine, 2018, 28, 491-501.	2.3	68
43	Effect of Aliskiren on Progression of Coronary Disease in Patients With Prehypertension. JAMA - Journal of the American Medical Association, 2013, 310, 1135.	3.8	67
44	Predicting the development of in-hospital cardiogenic shock in patients with ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention: the ORBI risk score. European Heart Journal, 2018, 39, 2090-2102.	1.0	66
45	Tricuspid annuloplasty versus a conservative approach in patients with functional tricuspid regurgitation undergoing left-sided heart valve surgery: A study-level meta-analysis. International Journal of Cardiology, 2017, 240, 138-144.	0.8	64
46	Hemodynamic Deterioration of Surgically Implanted Bioprosthetic Aortic Valves. Journal of the American College of Cardiology, 2018, 72, 241-251.	1.2	64
47	Predictors and Impact of Myocardial InjuryÂAfter Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2015, 66, 2075-2088.	1.2	63
48	Outcomes From Transcatheter Aortic Valve Replacement in Patients With Low-Flow, Low-Gradient Aortic Stenosis and Left Ventricular Ejection Fraction Less Than 30%. JAMA Cardiology, 2019, 4, 64.	3.0	63
49	Spotty calcification and plaque vulnerability in vivo: frequency-domain optical coherence tomography analysis. Cardiovascular Diagnosis and Therapy, 2014, 4, 460-9.	0.7	63
50	Factors underlying regression of coronary atheroma with potent statin therapy. European Heart Journal, 2013, 34, 1818-1825.	1.0	61
51	Visit-to-visit cholesterol variability correlates with coronary atheroma progression and clinical outcomes. European Heart Journal, 2018, 39, 2551-2558.	1.0	61
52	Remnant cholesterol, coronary atheroma progression and clinical events in statin-treated patients with coronary artery disease. European Journal of Preventive Cardiology, 2020, 27, 1091-1100.	0.8	61
53	Future of transcatheter aortic valve implantation — evolving clinical indications. Nature Reviews Cardiology, 2018, 15, 57-65.	6.1	60
54	Long-Term Outcomes in Patients With New-Onset Persistent Left Bundle Branch Block Following TAVR. JACC: Cardiovascular Interventions, 2019, 12, 1175-1184.	1.1	60

#	Article	IF	CITATIONS
55	Visit-to-Visit Blood Pressure Variability, Coronary Atheroma Progression, and Clinical Outcomes. JAMA Cardiology, 2019, 4, 437.	3.0	59
56	Effect of C-Reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients With High-Risk Vascular Disease. JAMA Cardiology, 2020, 5, 1136.	3.0	59
57	Atheroma Progression in Hyporesponders to Statin Therapy. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 990-995.	1.1	58
58	Predictors and Association With Clinical Outcomes of the Changes in Exercise Capacity After Transcatheter Aortic Valve Replacement. Circulation, 2017, 136, 632-643.	1.6	58
59	Long-Term Outcomes Following Surgical Aortic Bioprosthesis Implantation. Journal of the American College of Cardiology, 2018, 71, 1401-1412.	1.2	57
60	Sex-Related Differences of Coronary Atherosclerosis Regression Following Maximally Intensive Statin Therapy. JACC: Cardiovascular Imaging, 2014, 7, 1013-1022.	2.3	54
61	Serial Changes in Cognitive Function Following Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2016, 68, 2129-2141.	1.2	54
62	Cholesterol Crystals Associate With Coronary Plaque Vulnerability InÂVivo. Journal of the American College of Cardiology, 2015, 65, 630-632.	1,2	52
63	6-Month Outcomes of the TricValveÂSystem in Patients With Tricuspid Regurgitation. JACC: Cardiovascular Interventions, 2022, 15, 1366-1377.	1.1	51
64	High-Intensity Statin Therapy Alters the Natural History of Diabetic Coronary Atherosclerosis: Insights From SATURN. Diabetes Care, 2014, 37, 3114-3120.	4.3	50
65	Sex Differences in Nonculprit Coronary Plaque Microstructures on Frequency-Domain Optical Coherence Tomography in Acute Coronary Syndromes and Stable Coronary Artery Disease. Circulation: Cardiovascular Imaging, 2016, 9, .	1.3	49
66	Near-Infrared Spectroscopy Enhances Intravascular Ultrasound Assessment of Vulnerable Coronary Plaque. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 2423-2431.	1.1	48
67	Myocardial Injury After Transaortic VersusÂTransapical Transcatheter Aortic ValveÂReplacement. Annals of Thoracic Surgery, 2015, 99, 2001-2009.	0.7	47
68	Management of cardiogenic shock complicating acute myocardial infarction: A review. Clinical Cardiology, 2019, 42, 484-493.	0.7	47
69	The Utility of Rapid Atrial Pacing Immediately Post-TAVR to Predict the Need for Pacemaker Implantation. JACC: Cardiovascular Interventions, 2020, 13, 1046-1054.	1.1	47
70	Initial Experience of Transcatheter MitralÂValve Replacement With a NovelÂTranscatheter Mitral Valve. Journal of the American College of Cardiology, 2015, 66, 1011-1019.	1.2	46
71	Myocardial â€~no-reflow' — Diagnosis, pathophysiology and treatment. International Journal of Cardiology, 2013, 167, 1798-1806.	0.8	45
72	Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV). American Heart Journal, 2016, 176, 83-92.	1.2	45

#	Article	IF	Citations
73	Confirmation of the Intracoronary Near-Infrared Spectroscopy Threshold of Lipid-Rich Plaques That Underlie ST-Segment–Elevation Myocardial Infarction. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 1010-1015.	1.1	45
74	Cardiac magnetic resonance derived late microvascular obstruction assessment post ST-segment elevation myocardial infarction is the best predictor of left ventricular function: a comparison of angiographic and cardiac magnetic resonance derived measurements. International Journal of Cardiovascular Imaging, 2012, 28, 1971-1981.	0.7	44
<b>7</b> 5	Exploring coronary atherosclerosis with intravascular imaging. International Journal of Cardiology, 2013, 168, 670-679.	0.8	44
76	Warfarin Use Is Associated With Progressive Coronary Arterial Calcification. JACC: Cardiovascular Imaging, 2018, 11, 1315-1323.	2.3	44
77	Long-Term Outcomes of the FORMA Transcatheter Tricuspid Valve Repair System for the Treatment of SevereÂTricuspid Regurgitation. JACC: Cardiovascular Interventions, 2019, 12, 1438-1447.	1.1	44
78	Plaque microstructures in patients with coronary artery disease who achieved very low low-density lipoprotein cholesterol levels. Atherosclerosis, 2015, 242, 490-495.	0.4	43
79	Highâ€Sensitivity Câ€Reactive Protein Discordance With Atherogenic Lipid Measures and Incidence of Atherosclerotic Cardiovascular Disease in Primary Prevention: The ARIC Study. Journal of the American Heart Association, 2020, 9, e013600.	1.6	43
80	Impact of Baseline Lipoprotein and C-Reactive Protein Levels on Coronary Atheroma Regression Following High-Intensity Statin Therapy. American Journal of Cardiology, 2014, 114, 1465-1472.	0.7	42
81	Regression of coronary atherosclerosis with infusions of the high-density lipoprotein mimetic CER-001 in patients with more extensive plaque burden. Cardiovascular Diagnosis and Therapy, 2017, 7, 252-263.	0.7	42
82	Impact of Massive or Torrential Tricuspid Regurgitation in Patients Undergoing Transcatheter Tricuspid Valve Intervention. JACC: Cardiovascular Interventions, 2020, 13, 1999-2009.	1.1	42
83	Antiatherosclerotic Effects of Long-Term Maximally Intensive Statin Therapy After Acute Coronary Syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 2465-2472.	1.1	41
84	Total cholesterol/HDL-cholesterol ratio discordance with LDL-cholesterol and non-HDL-cholesterol and incidence of atherosclerotic cardiovascular disease in primary prevention: The ARIC study. European Journal of Preventive Cardiology, 2020, 27, 1597-1605.	0.8	41
85	Assessing the impact of PCSK9 inhibition on coronary plaque phenotype with optical coherence tomography: rationale and design of the randomized, placebo-controlled HUYGENS study. Cardiovascular Diagnosis and Therapy, 2021, 11, 120-129.	0.7	41
86	Outcomes of transcatheter tricuspid valve intervention by right ventricular function: a multicentre propensity-matched analysis. EuroIntervention, 2021, 17, e343-e352.	1.4	41
87	Myeloperoxidase levels predict accelerated progression of coronary atherosclerosis in diabetic patients: Insights from intravascular ultrasound. Atherosclerosis, 2014, 232, 377-383.	0.4	40
88	Neurological damage after transcatheter aortic valve implantation compared with surgical aortic valve replacement in intermediate risk patients. Clinical Research in Cardiology, 2016, 105, 508-517.	1.5	40
89	Latest-Generation Transcatheter Aortic Valve Replacement Devices and Procedures. Canadian Journal of Cardiology, 2017, 33, 1082-1090.	0.8	39
90	Frequency-Domain Optical Coherence Tomographic Analysis of Plaque Microstructures at Nonculprit Narrowings in Patients Receiving Potent Statin Therapy. American Journal of Cardiology, 2014, 114, 549-554.	0.7	37

#	Article	lF	CITATIONS
91	Coronary $\hat{l}^2$ 2-adrenoreceptors mediate endothelium-dependent vasoreactivity in humans: novel insights from an in vivo intravascular ultrasound study. European Heart Journal, 2012, 33, 495-504.	1.0	36
92	Left Main Coronary Atherosclerosis Progression, Constrictive Remodeling, and Clinical Events. JACC: Cardiovascular Interventions, 2013, 6, 29-35.	1.1	36
93	Infective Endocarditis Following Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2019, 12, e007938.	1.4	36
94	Blood Disorders in Patients Undergoing Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2019, 12, 1-11.	1.1	36
95	Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: Insights from SATURN. Atherosclerosis, 2017, 263, 137-144.	0.4	35
96	Feasibility, safety, and efficacy of transcatheter aortic valve replacement without balloon predilation: A systematic review and metaâ€analysis. Catheterization and Cardiovascular Interventions, 2017, 90, 839-850.	0.7	33
97	High-Risk Coronary Atheroma. Journal of the American College of Cardiology, 2014, 63, 1134-1140.	1.2	32
98	Outcomes of TTVI in Patients With Pacemaker or Defibrillator Leads. JACC: Cardiovascular Interventions, 2020, 13, 554-564.	1.1	32
99	Impact of anticoagulation therapy on valve haemodynamic deterioration following transcatheter aortic valve replacement. Heart, 2018, 104, 814-820.	1.2	31
100	Transcatheter mitral valve implantation for inoperable severely calcified native mitral valve disease: A systematic review. Catheterization and Cardiovascular Interventions, 2016, 87, 540-548.	0.7	27
101	Multiple risk factor intervention and progression of coronary atherosclerosis in patients with type 2 diabetes mellitus. European Journal of Preventive Cardiology, 2013, 20, 209-217.	0.8	26
102	Transcatheter Tricuspid Valve Intervention in Patients With Right Ventricular Dysfunction or Pulmonary Hypertension. Circulation: Cardiovascular Interventions, 2021, 14, e009685.	1.4	26
103	Progression of coronary atherosclerosis in stable patients with ultrasonic features of high-risk plaques. European Heart Journal Cardiovascular Imaging, 2014, 15, 1035-1041.	0.5	25
104	Prosthetic Mitral Surgical Valve in Transcatheter Aortic Valve ReplacementÂRecipients. JACC: Cardiovascular Interventions, 2017, 10, 1973-1981.	1.1	25
105	The Distinctive Nature of Atherosclerotic Vascular Disease in Diabetes: Pathophysiological and Morphological Insights. Current Diabetes Reports, 2012, 12, 280-285.	1.7	24
106	Artificial Intelligence in Intracoronary Imaging. Current Cardiology Reports, 2020, 22, 46.	1.3	24
107	Feasibility and Safety of Same-Day Discharge Following Transfemoral Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2022, 15, 575-589.	1.1	24
108	Atrial fibrillation, progression of coronary atherosclerosis and myocardial infarction. European Journal of Preventive Cardiology, 2017, 24, 373-381.	0.8	23

#	Article	IF	CITATIONS
109	Implications of Total to High-Density Lipoprotein Cholesterol Ratio Discordance With Alternative Lipid Parameters for Coronary Atheroma Progression and Cardiovascular Events. American Journal of Cardiology, 2016, 118, 647-655.	0.7	21
110	Valve-in-valve transcatheter aortic valve implantation versus repeat surgical aortic valve replacement in patients with a failed aortic bioprosthesis. EuroIntervention, 2022, 17, 1227-1237.	1.4	21
111	The utilization of single versus double Perclose devices for transfemoral aortic valve replacement access site closure: Insights from Cleveland Clinic Aortic Valve Center. Catheterization and Cardiovascular Interventions, 2020, 96, 442-447.	0.7	20
112	Progression of ultrasound plaque attenuation and low echogenicity associates with major adverse cardiovascular events. European Heart Journal, 2020, 41, 2965-2973.	1.0	19
113	Coronary atheroma progression rates in men and women following high-intensity statin therapy: A pooled analysis of REVERSAL, ASTEROID and SATURN. Atherosclerosis, 2016, 254, 78-84.	0.4	18
114	Dispositivos de protección embólica durante elÂTAVI: evidencias eÂincertidumbres actuales. Revista Espanola De Cardiologia, 2016, 69, 962-972.	0.6	17
115	Inflammation, plaque progression and vulnerability: evidence from intravascular ultrasound imaging. Cardiovascular Diagnosis and Therapy, 2015, 5, 280-9.	0.7	16
116	Oral Calcium Supplements Associate With Serial Coronary Calcification. JACC: Cardiovascular Imaging, 2021, 14, 259-268.	2.3	15
117	Therapeutic modulation of the natural history of coronary atherosclerosis: lessons learned from serial imaging studies. Cardiovascular Diagnosis and Therapy, 2016, 6, 282-303.	0.7	13
118	Intravascular Ultrasound and Near-Infrared Spectroscopic Characterization of Thin-Cap Fibroatheroma. American Journal of Cardiology, 2017, 119, 372-378.	0.7	13
119	Clinical and Technical Characteristics of Coronary Angiography and Percutaneous Coronary Interventions Performed before and after Transcatheter Aortic Valve Replacement with a Balloon-Expandable Valve. Journal of Interventional Cardiology, 2019, 2019, 1-9.	0.5	13
120	Transcatheter aortic valve replacement: relative safety and efficacy of the procedure with different devices. Expert Review of Medical Devices, 2019, 16, 11-24.	1.4	13
121	Caval Valve Implantation (CAVI): An Emerging Therapy for Treating Severe Tricuspid Regurgitation. Journal of Clinical Medicine, 2021, 10, 4601.	1.0	13
122	Statin-induced coronary artery disease regression rates differ in men and women. Current Opinion in Lipidology, 2015, 26, 276-281.	1.2	12
123	Regression of coronary atheroma with statin therapy. Current Opinion in Endocrinology, Diabetes and Obesity, 2016, 23, 131-137.	1.2	12
124	The beneficial effects of raising high-density lipoprotein cholesterol depends upon achieved levels of low-density lipoprotein cholesterol during statin therapy: Implications for coronary atheroma progression and cardiovascular events. European Journal of Preventive Cardiology, 2016, 23, 474-485.	0.8	12
125	Transcatheter aortic valve implantation in patients with small aortic annuli using a 20â€mm balloon-expanding valve. Heart, 2017, 103, 148-153.	1.2	12
126	Therapeutic Agents Targeting Cardiometabolic Risk for Preventing and Treating Atherosclerotic Cardiovascular Diseases. Clinical Pharmacology and Therapeutics, 2018, 104, 257-268.	2.3	12

#	Article	IF	CITATIONS
127	Association of Serum Lipoprotein (a) Levels and Coronary Atheroma Volume by Intravascular Ultrasound. Journal of the American Heart Association, 2020, 9, e018023.	1.6	12
128	Intraventricular Conduction Disturbances After Transcatheter Aortic Valve Implantation. Interventional Cardiology Review, 2020, 15, e11.	0.7	12
129	In vivovisualization of lipid coronary atheroma with intravascular near-infrared spectroscopy. Expert Review of Cardiovascular Therapy, 2017, 15, 775-785.	0.6	11
130	Embolic Protection Devices During TAVI: Current Evidence and Uncertainties. Revista Espanola De Cardiologia (English Ed ), 2016, 69, 962-972.	0.4	10
131	Reported Versus "Real―Incidence of New Pacemaker Implantation Post-Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2016, 68, 2387-2389.	1.2	10
132	Povidone-iodine Irrigation - A Possible Alternative To Lead Extraction. Indian Pacing and Electrophysiology Journal, 2011, 11, 115-9.	0.3	10
133	Imaging Progression of Coronary Atherosclerosis. Circulation Journal, 2013, 77, 3-10.	0.7	9
134	Subclinical Leaflet Thrombosis and Clinical Outcomes after TAVR: A Systematic Review and Meta-Analysis. Structural Heart, 2018, 2, 223-228.	0.2	9
135	Left main percutaneous coronary interventionâ€"Radial versus femoral access: A systematic analysis. Catheterization and Cardiovascular Interventions, 2020, 95, E201-E213.	0.7	9
136	Outcomes of transcatheter aortic valve replacement in patients with cognitive dysfunction. Journal of the American Geriatrics Society, 2021, 69, 1363-1369.	1.3	9
137	Coronary Endothelium-Dependent Vasoreactivity and Atheroma Volume in Subjects With Stable, Minimal Angiographic Disease Versus Non–ST-Segment–Elevation Myocardial Infarction. Circulation: Cardiovascular Imaging, 2013, 6, 674-682.	1.3	8
138	The FORMA Repair System. Interventional Cardiology Clinics, 2018, 7, 47-55.	0.2	8
139	Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2016, 9, 364-366.	1.1	7
140	The Caval-Aortic Access for Performing TAVR. Journal of the American College of Cardiology, 2017, 69, 522-525.	1.2	7
141	Plaque burden, microstructures and compositions underachieving very low LDL-C levels. Current Opinion in Endocrinology, Diabetes and Obesity, 2017, 24, 122-132.	1.2	7
142	Lipid Lowering Therapy to Modify Plaque Microstructures:. Journal of Atherosclerosis and Thrombosis, 2017, 24, 360-372.	0.9	7
143	Three―and 6â€month optical coherence tomographic surveillance following percutaneous coronary intervention with the Angiolite® drugâ€eluting stent: The ANCHOR study. Catheterization and Cardiovascular Interventions, 2018, 91, 435-443.	0.7	7
144	Tricuspid but not Mitral Regurgitation Determines Mortality After TAVI in Patients With Nonsevere Mitral Regurgitation. Revista Espanola De Cardiologia (English Ed ), 2018, 71, 357-364.	0.4	7

#	Article	IF	Citations
145	Balancing the Risks of Thrombosis and Bleeding Following Transcatheter Aortic Valve Implantation: Current State-of-Evidence. Current Pharmaceutical Design, 2016, 22, 1904-1910.	0.9	7
146	Implications of GLAGOV study. Current Opinion in Lipidology, 2017, 28, 465-469.	1.2	6
147	Impact of baseline conduction abnormalities on outcomes after transcatheter aortic valve replacement with <scp>SAPIEN</scp> â€3. Catheterization and Cardiovascular Interventions, 2021, 98, E127-E138.	0.7	6
148	"Framing―the Vessel. Journal of the American College of Cardiology, 2012, 59, 1038-1039.	1.2	5
149	Coronary atheroma composition and its association with segmental endothelial dysfunction in non-ST segment elevation myocardial infarction: novel insights with radiofrequency (iMAP) intravascular ultrasonography. International Journal of Cardiovascular Imaging, 2015, 31, 247-257.	0.7	5
150	Triglyceride-to-High-Density Lipoprotein Cholesterol Ratio and Vulnerable Plaque Features With Statin Therapy in Diabetic Patients With Coronary Artery Disease. JACC: Cardiovascular Imaging, 2018, 11, 1721-1723.	2.3	5
151	Roles of Cardiac Computed Tomography in Guiding Transcatheter Tricuspid Valve Interventions. Current Cardiology Reports, 2021, 23, 114.	1.3	5
152	Utilization of IVUS improves all-cause mortality in patients undergoing invasive coronary angiography. Atherosclerosis Plus, 2021, 43, 10-17.	0.3	5
153	Plaque microstructures during metformin therapy in type 2 diabetic subjects with coronary artery disease: optical coherence tomography analysis. Cardiovascular Diagnosis and Therapy, 2021, 12, 0-0.	0.7	5
154	Comparing Coronary Atheroma Progression Rates and Coronary Events in the United States, Canada, Latin America, and Europe. American Journal of Cardiology, 2016, 118, 1616-1623.	0.7	4
155	LDL-C Targets in Secondary Prevention: How Low Should We Go?. Current Cardiovascular Risk Reports, 2019, 13, 1.	0.8	4
156	Transcatheter Tricuspid Valve Intervention in Patients With Previous Left Valve Surgery. Canadian Journal of Cardiology, 2021, 37, 1094-1102.	0.8	4
157	Surgical versus medical management of infective endocarditis after TAVR. Catheterization and Cardiovascular Interventions, 2022, 99, 1592-1596.	0.7	4
158	HbA1c, Coronary atheroma progression and cardiovascular outcomes. American Journal of Preventive Cardiology, 2022, 9, 100317.	1.3	4
159	Effects of aliskiren in diabetic and non-diabetic patients with coronary artery disease: Insights from AQUARIUS. Atherosclerosis, 2015, 243, 553-559.	0.4	3
160	Non-invasive volumetric assessment of aortic atheroma: a core laboratory validation using computed tomography angiography. International Journal of Cardiovascular Imaging, 2016, 32, 121-129.	0.7	3
161	An Optimized Approach for Transfemoral Transcatheter Aortic Valve Implantation: A Comprehensive Review and Current Evidence. Cardiovascular Revascularization Medicine, 2020, 21, 1034-1040.	0.3	3
162	Drug-Eluting Stent Treatment of a Radiation-Induced Left Internal Mammary Arterial Graft Stenosis. Circulation Journal, 2008, 72, 1904-1906.	0.7	2

#	Article	IF	CITATIONS
163	Response to Comment on Stegman et al. High-Intensity Statin Therapy Alters the Natural History of Diabetic Coronary Atherosclerosis: Insights From SATURN. Diabetes Care 2014;37:3114–3120. Diabetes Care, 2015, 38, e28-e29.	4.3	2
164	Reply. Journal of the American College of Cardiology, 2018, 72, 587-588.	1.2	2
165	C-reactive protein levels and plaque regression with evolocumab: Insights from GLAGOV. American Journal of Preventive Cardiology, 2020, 3, 100091.	1.3	2
166	Machine Learning Risk Model for Predicting In-hospital Mortality for Patients with Infective Endocarditis After Transcatheter Aortic Valve Replacement. Cardiovascular Revascularization Medicine, 2021, , .	0.3	2
167	Inadvertent anastomosis of internal mammary artery to great cardiac vein: a rare complication of coronary artery bypass surgery. Texas Heart Institute Journal, 2009, 36, 626-7.	0.1	2
168	Early Resolution of New-Onset Left Bundle Branch Block After Transcatheter Aortic Valve Implantation With the SAPIEN 3 Valve. American Journal of Cardiology, 2022, 168, 117-127.	0.7	2
169	Evaluation of the 2021 European Society of Cardiology guidelines in pre-existing right bundle branch block patients undergoing transcatheter aortic valve implantation with a balloon-expandable valve. European Heart Journal Open, 2022, 2, .	0.9	2
170	Transcatheter Aortic Valve Replacement–Associated Infective Endocarditis: Comparison of Early, Intermediate, and Late-Onset Cases. Structural Heart, 2022, 6, 100005.	0.2	2
171	Determinants of Plaque Progression Despite Very Low Low-Density Lipoprotein–Cholesterol Levels With the PCSK9 Inhibitor, Evolocumab. JACC: Cardiovascular Imaging, 2022, 15, 709-711.	2.3	2
172	Phenotypic Features of Coronary Atheroma in Diabetic and Nondiabetic Patients With Low-Density Lipoprotein CholesterolÂ<55Amg/dL. JACC: Cardiovascular Imaging, 2022, 15, 1166-1169.	2.3	2
173	Left main coronary arterial endothelial function and heterogenous segmental epicardial vasomotor reactivity in vivo: novel insights with intravascular ultrasonography. European Heart Journal Cardiovascular Imaging, 2014, 15, 1270-1280.	0.5	1
174	The impact of lumen size and microvascular resistance on Fourier-domain optical coherence tomography (FD-OCT) coronary measurements. International Journal of Cardiology, 2014, 174, 210-211.	0.8	1
175	High-Density Lipoprotein–Targeted Therapies—Not Dead Yet—Reply. JAMA Cardiology, 2018, 3, 1255.	3.0	1
176	Evolution of Procedural and Clinical Outcomes After Balloon-Expanding Transcatheter Aortic Valve Implantation In Canada (from the Early Canadian Experience and SOURCE XT Registries). American Journal of Cardiology, 2018, 122, 461-467.	0.7	1
177	Coronary atherosclerotic plaque progression: contributing factors in statin-treated patients. Expert Review of Cardiovascular Therapy, 2020, 18, 873-880.	0.6	1
178	Conduction disturbances following trancatheter aortic valve implantation: increasing the †pace†towards prospective evidence. European Heart Journal, 2020, 41, 2782-2784.	1.0	1
179	Incidence, treatment, and outcomes of acute myocardial infarction following transcatheter or surgical aortic valve replacement. Catheterization and Cardiovascular Interventions, 2021, , .	0.7	1
180	Risk Stratification and Management of Advanced Conduction Disturbances Following TAVI in Patients With Pre-Existing RBBB. Structural Heart, 2022, 6, 100006.	0.2	1

#	Article	IF	CITATIONS
181	Conduction Disturbance, Pacemaker Rates, and Hospital Length of Stay Following Transcatheter Aortic Valve Implantation with the Sapien 3 Valve. Structural Heart, 2022, , 100019.	0.2	1
182	Complete extrusion of an implantable cardiac defibrillator. Europace, 2008, 10, 173-174.	0.7	0
183	Intracoronary IVUS for Evaluation of Atherosclerosis Progression. Current Cardiovascular Imaging Reports, 2012, 5, 239-248.	0.4	O
184	Intracoronary Optical Coherence Tomography. Journal of the American College of Cardiology, 2013, 62, 1759-1760.	1.2	0
185	Reply. JACC: Cardiovascular Interventions, 2016, 9, 2366-2368.	1.1	0
186	The challenging realm of neurocognitive evaluation following transcatheter aortic valve implantation. Archives of Cardiovascular Diseases, 2017, 110, 203-205.	0.7	0
187	Blood Pressure Variability and Arterial Stiffness—Chicken or Egg?—Reply. JAMA Cardiology, 2019, 4, 1050.	3.0	0
188	Unraveling the Cardiovascular PROSPECTs of Patients With Prediabetes. JACC: Cardiovascular Imaging, 2019, 12, 742-744.	2.3	0
189	What Is the Role of Cardiac Magnetic Resonance Imaging in Transcatheter Management of Aortic Valve Stenosis?. Structural Heart, $0$ , , $1$ - $13$ .	0.2	0
190	Monitoring the Progression and Regression of Coronary Atherosclerosis with Intravascular Ultrasound. Contemporary Cardiology, 2014, , 67-79.	0.0	0
191	Additional Lipid Targets to Modulate Atherosclerotic Plaques beyond LDL-C Lowering. Journal of the Japanese Coronary Association, 2016, 22, 217-227.	0.0	0
192	Impact of Timing of Infective Endocarditis After Transcatheter Aortic Valve Implantation on Mortality. American Journal of Cardiology, 2022, 168, 178-179.	0.7	0